I would agree that the license bringing in some necessary cash is a good thing. But to me it is absolutely a business failure selling equity units for $1US with whole warrants exercisable at $1US when 2 years ago the units were selling for $2US with warrants exercisable at $3US. The science has moved forward in some very positive ways and there hasn’t been enough dilution to justify the valuation discount. Is this a “buddy” discount? Or is this just one more example of Don with no plan in a state of desperation?

I find it hard to understand why there has been a failure by management to obtain an investment in the company by one of the BP trial partners. Is the management and BoD afraid to have someone at the table who actually knows what they are talking about from a business perspective. To me that would be a refreshing change from the current collection of business duds.

As has been discussed before the sale of Constellation, with similar or perhaps even lesser scientific achievement, set a nice valuation bar for a mid stage company with an epigenetic cancer program. Zenith seems to be moving away from that bar instead of closing the gap. Lack of any discernible business skill at Zenith seems to be once again failing some very positive scientific achievement.